Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

ACT-Accelerator Strategic Plan & Budget October 2021 to September 2022
Enhancing equity in access to COVID-19 tools
28 October 2021

Major Vx milestones over the next 12 months
• By April 2022: Generate clinical evidence for expanded and optimized use of available vaccines, including for 3rd dose strategies, with a focus on LMIC use, and consistent with the Charter for Equitable Access to COVID-19 Tools
• Invest in next generation vaccines with optimized profiles, including those with potential to mitigate impact of future variants of concern. First interim efficacy results from second generation portfolio expected by Q1 2022
• Dec 2021: Allocate all available doses including the 1.4 billion doses currently forecasted to be available to the AMC92 by the end of 2021 per the September COVAX Facility supply forecast15
• Focus on supporting low-income countries, which are currently receiving fewer than one in seven of non-COVAX supplied doses – and 27 of the AMC91 have no non-COVAX supply
• Provide additional COVAX delivery funding as part of a coordinated COVAX effort to continue to support countries to scale-up delivery and mitigate key risks to routine immunisation and other essential health services, with a focus on countries without sufficient other sources of external financing

Vaccines priorities and associated activities
1. Continue to build a robust foundation for countries’ vaccination coverage ambitions, by pooling demand, supply & resources, complemented by other procurement mechanisms
• Implement an updated country participation model, with a focus on AMC countries while offering SFPs the opportunity to procure future doses and participate beyond procurement
• Continue to support countries in achieving their vaccination coverage targets, through Advance Purchase Agreement doses and dose donations (alongside other sources of supply)
• Aspire to provide AMC countries at least 600 million doses, in addition to already secured supply
• Sustain a robust and diverse portfolio, able to absorb shocks and respond to preferences
2. Support a portfolio and pipeline of effective, affordable and scalable vaccines in
the context of variants, boosters, sustained transmission and emerging platform preferences, ensuring sustained and early access to new vaccines, shaping the market for the long term
• Support investments in the development of improved product characteristics preferred by AMC92 and support tech transfer and manufacturing scale-up via maintenance of a supply marketplace and, if capacity and resources are available, the establishment of sustainable manufacturing capacity in regions lacking significant capacity, with support to overcome IP barriers where needed
• Continue engagement with countries and manufacturers on market-shaping to support the development of a healthy market and affordably priced vaccines
• Tackle evidence generation more systematically when there are meaningful differences between HICs and L(M)ICs and when interventions could prevent and control disease, and to manage future risk of additional variants
https://www.who.int/docs/default-source/coronaviruse/act-accelerator-strategic-plan.pdf?sfvrsn=70e4d906_5&download=true